Ituran Location and Control Ltd. reported record revenue, profitability, and cash flow in Q2, driven by recurring revenue now making up 76% of total income. The company trades at reasonable valuations with potential 27% upside if growth and margins continue. Strong OEM partnerships, especially in South America, and disciplined capital returns support its investment case, while Big Data initiatives provide long-term growth opportunities. The analyst maintains a Buy rating, expecting steady returns through 2026 if subscriber growth and project traction persist.
Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...
DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with ins...
Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...
Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...
The global anthracite market, valued at $11.9 billion in 2025, is projected to grow to $16.8 billion by 2035 with a 3.5% CAGR. Growth is fueled by rising demand in steel production, water filtration, and advanced industrial uses due to anthracite's h...
